Phaseline

Companies › Telios Pharma

Telios Pharma: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology, Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TL-925–Phase 2Allergic Conjunctivitis–
TL-895
Irreversible tyrosine kinase inhibitor
–Phase 1MyelofibrosisApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06686472TL-925Phase 2Allergic ConjunctivitisImmunologyDec 2024
NCT07220408TL-925Phase 2Allergic ConjunctivitisImmunologyFeb 2026
NCT05280509TL-895Phase 1MyelofibrosisOncologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Molecure Tavotek Biotherapeutics Xizang Haisco Pharmaceutical Antengene Biologics Ganzhou Hemay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.